ReviewCureus2025
Selective Serotonin Reuptake Inhibitors (SSRIs) and Surgical Bleeding in Plastic Surgery: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Psychological Resilience in Surgery: Psychobiological Pathways, Clinical Impact, and Perioperative Modulation-A Narrative Review.Journal of personalized medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are first-line pharmacotherapy for various psychiatric disorders. These medications adversely affect hemostasis by limiting serotonin reuptake crucial for platelet aggregation. Increased bleeding risk vs SSRI discontinuation syndrome may have important clinical considerations for plastic and reconstructive surgeries (PRSs). With the increasing use of SSRIs, understanding the associated risk of bleeding in soft-tissue surgeries is crucial for optimizing patient outcomes and ensuring safety. In this systematic review, the National Center for Biotechnology Information (NCBI) and Embase databases were searched for publications addressing SSRI consumption and bleeding outcomes in PRS and soft-tissue procedures. Five retrospective cohort studies on SSRIs and bleeding were identified, differing in surgical types, study designs, and reporting of bleeding outcomes, precluding meta-analysis. Post-operative bleeding rates ranged from 1.9% to 2.6%. A U.S. study on breast cosmetic procedures reported a 4.14-fold increase in hematoma reoperations (odds ratio (OR) 4.14; 95% CI 1.90-9.04), while a Danish study on breast oncologic procedures showed a 2.7-fold increased risk (OR 2.7; 95% CI 1.6-4.4). Another Danish study found no increased risk of post-operative blood transfusion (OR 1.2; 95% CI 0.7-1.9). Two U.S. studies on facial procedures found no significant differences in bleeding events, though both had low statistical power. Overall, the risk of significant bleeding complications in breast and facial PRS procedures appears low, with SSRI use increasing hematoma reoperation risk for breast procedures to less than 5%, without evidence of life-threatening bleeding. Conclusions regarding SSRI-related bleeding in facial plastic surgery are limited due to the overall quality of existing studies, which often rely on case reports rather than higher-quality research designs, such as cohort or prospective analyses. Therefore, further high-level evaluations of SSRI-related bleeding are necessary, particularly focusing on procedures involving the face, extremities, and flap surgeries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.